Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Biotechnologijos

Mr. John J. Kirby CPA

Chief Financial Officer

Dr. Sudhir  Agrawal D.Phil., F.R.S.C.

Scientific Advisor

Mr. Louis J. Arcudi III, M.B.A., MBA

Adviser

Mr. John  Taylor

Chief Executive Officer & Director

Mr. Daniel  Salain

Chief Operating Officer

Mr. Bryant David Lim

Chief Bus. Officer & Gen. Counsel

Mr. Andy  Jordan

Chief Strategy Officer

Dr. Carl  Kraus M.D.

Chief Medical Officer

Dr. Joanna Caroline Horobin Ch.B, M.B.

Advisor

Dr. Shah  Rahimian M.D., Ph.D.

Medical Director & Global Clinical Lead for Oncology

Mr. John C. Taylor

Pavadinimas	Rinkos kapitalizacija
Sorrento Therapeutics, Inc.	0M
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
Gubra A/S	0M
CytoTools AG	0M
Hofseth BioCare ASA	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M

Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc. Konkurentų sąrašas

Pagrindiniai konkurentai